Mcl-1 is regulated by IL-6 and mediates the survival activity of the cytokine in a model of late stage prostate carcinoma

Advances in Experimental Medicine and Biology

Volumn 617, Issue , 2008, Pages 547-555

  Cavarretta, Ilaria Teresa ^a   Neuwirt, Hannes ^a   Zaki, Mohamed H ^a   Steiner, Hannes ^a   Hobisch, Alfred ^a   Nemeth, Jeffrey A ^a   Culig, Zoran ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BCL 2; PROTEIN MCL 1; SMALL INTERFERING RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CNTO 328; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN;

APOPTOSIS; CANCER CELL CULTURE; CANCER STAGING; CELL SURVIVAL; CELL VIABILITY; CONFERENCE PAPER; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CARCINOMA; ARTICLE; CELL CULTURE; DISEASE COURSE; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MALE; METABOLISM; NEOPLASM; PROSTATE TUMOR;

ANTIBODIES, MONOCLONAL; APOPTOSIS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASMS, HORMONE-DEPENDENT; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 46749085910     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-69080-3_56     Document Type: Conference Paper

References (28)

1. Twillie DA, Eisenberger MA, Carducci MA, et al. (1995) Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 45: 542-9.
2. Yoon S, Seger R (2006) The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 24(1): 21- 44.
3. Rubinfeld H, Seger R (2005) The ERK cascade: a prototype of MAPK signaling. Mol Biotechnol 31(2): 151-74.
4. Sridhar SS, Hedley D, and Siu LL (2005) Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther 4(4): 677-85.
5. Shimada K, Nakamura M, Ishida E, et al. (2002) Contributions of mitogen-activated protein kinase and nuclear factor kappa B to N-(4-hydroxyphenyl)retinamide-induced apoptosis in prostate cancer cells. Mol Carcinog 35(3): 127-37.
6. Ricote M, Garcia-Tunon I, Bethencourt F, et al. (2006) The p38 transduction pathway in prostatic neoplasia. J Pathol 208(3): 401-7.
7. Hobisch A, Ramoner R, Fuchs D, et al. (2001) Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin Cancer Res 7(9): 2941-8.
8. Culig Z, Steiner H, Bartsch G, et al. (2005) Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 95: 497-505.
9. Fadeel B, Orrenius S (2005) Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease. J Intern Med 258(6): 479-517.
10. Jourdan M, Veyrune JL, Vos JD, et al. (2003) A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells. Oncogene 22(19): 2950-9.
11. Royuela M, Arenas MI, Bethencourt FR, et al. (2001) Immunoexpressions of p21, Rb, mcl-1 and bad gene products in normal, hyperplastic and carcinomatous human prostates. Eur Cytokine Netw 12(4): 654-63.
12. Krajewska M, Krajewski S, Epstein JI, et al. (1996) Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 148(5): 1567-76.
13. Krajewski S, Bodrug S, Krajewska M, et al. (1995) Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am J Pathol 146(6): 1309-19.
14. Derouet M, Thomas L, Cross A, et al. (2004) Granulocyte macrophage colony-stimulating factor signaling and proteasome inhibition delay neutrophil apoptosis by increasing the stability of Mcl-1. J Biol Chem 279(26): 26915-21.
15. Boucher MJ, Morisset J, Vachon PH, et al. (2000) MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem 79(3): 355-69.
16. Selzer E, Thallinger C, Hoeller C, et al. (2002) Betulinic acid-induced Mcl-1 expression in human melanoma - mode of action and functional significance. Mol Med 8(12): 877-84.
17. Steiner H, Godoy-Tundidor S, Rogatsch H, et al. (2003) Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. Am J Pathol 162(2): 655-63.
18. Borsellino N, Belldegrun A, Bonavida B (1995) Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 55(20): 4633-9.
19. Borsellino N, Bonavida B, Ciliberto G, et al. (1999) Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. Cancer 85(1): 134 - 44.
20. Pu YS, Hour TC, Chuang SE, et al. (2004) Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells. Prostate 60(2): 120-9.
21. Smith PC, Hobisch A, Lin DL, et al. (2001) Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev 12(1): 33 - 40.
22. Royuela M, Arenas MI, Bethencourt FR, et al. (2002) Regulation of proliferation/apoptosis equilibrium by mitogen-activated protein kinases in normal, hyperplastic, and carcinomatous human prostate. Hum Pathol 33(3): 299-306.
23. Raje N, Kumar S, Hideshima T, et al. (2005) Seliciclib (CYC202 or R-roscovitine), a smallmolecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood 106(3): 1042-7.
24. Puthier D, Derenne S, Barille S, et al. (1999) Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells. Br J Haematol, 107(2): 392-5.
25. Lee SO, Lou W, Johnson CS, et al. (2004) Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway. Prostate 60(3): 178-86.
26. Nam S, Buettner R, Turkson J, et al. (2005) Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci USA 102(17): 5998-6003.
27. Niu G, Bowman T, Huang M, et al. (2002) Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 21(46): 7001-10.
28. Zelivianski S, Spellman M, Kellerman M, et al. (2003) ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells. Int J Cancer 107(3): 478-85.